Skip to main content
Journal cover image

The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization.

Publication ,  Journal Article
Weissler, EH; Aboyans, V; Bauersachs, R; Brodmann, M; Nikol, S; Debus, S; Patel, MR; Jones, WS
Published in: JACC Cardiovasc Interv
April 12, 2021

Evidence for antithrombotic treatment following lower extremity revascularization (LER) for peripheral artery disease (PAD) is limited, leading to weak and conflicting guideline recommendations and heterogeneous practice patterns. This variability in post-LER antithrombotic treatment raises quality-of-care issues that have long been under-studied. This Viewpoint reviews the most updated guidelines, currently-available evidence, and contemporary data about practice patterns and practitioner opinions in this area. Particular attention is paid to distinctions between antiplatelet therapy, anticoagulant therapy, and combination therapy in light of the recent VOYAGER-PAD (Vascular Outcomes Study of ASA [acetylsalicylic acid] Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) trial. The implications of VOYAGER-PAD pertaining to various subgroups of patients undergoing LER are explored. Overall, this Viewpoint argues for consideration of post-LER therapy targeted at both platelet function and the coagulation cascade, though further LER-specific analyses, including expected VOYAGER-PAD sub-analyses, are needed.

Duke Scholars

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

April 12, 2021

Volume

14

Issue

7

Start / End Page

796 / 802

Location

United States

Related Subject Headings

  • Vascular Surgical Procedures
  • Treatment Outcome
  • Peripheral Arterial Disease
  • Lower Extremity
  • Humans
  • Fibrinolytic Agents
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weissler, E. H., Aboyans, V., Bauersachs, R., Brodmann, M., Nikol, S., Debus, S., … Jones, W. S. (2021). The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. JACC Cardiovasc Interv, 14(7), 796–802. https://doi.org/10.1016/j.jcin.2021.01.035
Weissler, E Hope, Victor Aboyans, Rupert Bauersachs, Marianne Brodmann, Sigrid Nikol, Sebastian Debus, Manesh R. Patel, and W Schuyler Jones. “The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization.JACC Cardiovasc Interv 14, no. 7 (April 12, 2021): 796–802. https://doi.org/10.1016/j.jcin.2021.01.035.
Weissler EH, Aboyans V, Bauersachs R, Brodmann M, Nikol S, Debus S, et al. The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. JACC Cardiovasc Interv. 2021 Apr 12;14(7):796–802.
Weissler, E. Hope, et al. “The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization.JACC Cardiovasc Interv, vol. 14, no. 7, Apr. 2021, pp. 796–802. Pubmed, doi:10.1016/j.jcin.2021.01.035.
Weissler EH, Aboyans V, Bauersachs R, Brodmann M, Nikol S, Debus S, Patel MR, Jones WS. The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. JACC Cardiovasc Interv. 2021 Apr 12;14(7):796–802.
Journal cover image

Published In

JACC Cardiovasc Interv

DOI

EISSN

1876-7605

Publication Date

April 12, 2021

Volume

14

Issue

7

Start / End Page

796 / 802

Location

United States

Related Subject Headings

  • Vascular Surgical Procedures
  • Treatment Outcome
  • Peripheral Arterial Disease
  • Lower Extremity
  • Humans
  • Fibrinolytic Agents
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology